ACINETOBACTER SPECIES
The Professional Medical Journal
www.theprofesional.com
ORIGINAL PROF-4723
DOI: 10.29309/TPMJ/18.4723
ACINETOBACTER SPECIES;
PREVALENCE AND SENSITIVITY PATTERN OF ACINETOBACTER SPECIES
AMONG CLINICAL ISOLATES OF TERTIARY CARE HOSPITAL
1. MBBS, M.Phil Microbiology
Demonstrator
Department of Pathology
Rahbar Medical & Dental College
(RMDC), Lahore.
2. MBBS, M.Phil Microbiology
Assistant Professor
Department of Pathology
Gujranwala Medical College,
Gujranwala.
3. MBBS, M.Phil Microbiology
Demonstrator
Department of Pathology
Ameerudin Medical College/
Shareef Medical & Dental College,
Lahore, Pakistan.
Correspondence Address:
Dr. Aneela Khawaja
M. Phil Microbiology (PGMI),
129-B, Phase-1, DHA, Lahore.
draneelakh@gmail.com
Article received on:
12/02/2018
Accepted for publication:
15/08/2018
Received after proof reading:
03/12/2018
Aneela Khawaja1, Faiqa Arshad2, Sadaf Aleem3
ABSTRACT… Introduction: The genetic competencies of bacteria and the resistance have
been impeding the usefulness of antibiotic therapy. There has been an alarming increase in
the infections caused by Acinetobacter spp. especially the multidrug resistance pattern has
narrowed the therapeutic ranges. Objectives: To determine the prevalence and antibiotic
sensitivity pattern of Acinetobacter spp., among clinical specimens of tertiary care hospital.
Study Design: Descriptive study. Place & Duration of Study: Pathology Department, PGMI,
from January 2015 to December 2015. Materials & Methods: Total 8465 clinical specimens were
inoculated. Acinetobacter spp. was identified and isolated by the preliminary microbiological
and biochemical tests. Antimicrobial susceptibility testing was implemented by modified
Kirby-Bauer disk diffusion method as per CLSI guidelines (2015). Results: Acinetobacter spp.
isolated in 234 (7.29%) clinical specimens among 3208 (37.89%) culture positive isolates. Out
of total 234 Acinetobacter spp. isolates 144 (61.54%) were recovered from male patients and 90
(38.46%) from female patients. the frequency of Acinetobacter spp. isolates was seen highest in
CSF (23.07%) and lowest in HVS (5.52%) specimens. Maximum samples were recovered from
surgical wards 85 (36.32%), while from pediatrics department only 20 (8.54%) samples. Only,
140 (59.82%) isolates were sensitive to tigecycline; while 216 isolates were (92.30%) resistant
to salbactam. Conclusion: The progressively increasing threat of Acinetobacter resistant
infections can be minimized by judicial use of antibiotics, and implementation of strict infection
control policy in health care settings.
Key words:
Acinetobacter spp. (species); ESKAPE Pathogens (E. Faecium, S. Aureus,
K. Pneumoniae, A. Baumannii, P. Aeruginosa and Enterobacter spp.); CLSI
(Clinical and Laboratory Standard Institute); MDR (Multidrug Resistance).
Article Citation: Khawaja A, Arshad F, Aleem S. Acinetobacter species; prevalence and
sensitivity pattern of acinetobacter species among clinical isolates of
tertiary care hospital. Professional Med J 2018; 25(12):1949-1953.
DOI: 10.29309/TPMJ/18.4723
INTRODUCTION
The genetic competencies of bacteria and careless
use of antibiotics have ensued in the well-known
expansion of resistance, impeding the usefulness
of antibiotic therapy. Resistance to single antibiotic
has further progressed into multidrug resistance
which favorably shields bacterial pathogens
against several frequently used therapeutic
agents.1 Acinetobacter baumannii belongs to one
of the six ESKAPE pathogens, whose infections
have recently been recognized as a grave
emerging problem.2 The major risk factors for
acquisition of infection with Acinetobcter spp., in
health care setting are: prolong hospitalization,
ICUs (ventilator associated pneumonia), surgical
procedures, blood stream infections (BSI), deviceassociated infections (urinary and intravascular
Professional Med J 2018;25(12):1949-1953.
catheters), and immunosuppression (renal
failure, chronic lung disease, diabetes, terminal
illnesses like cancer).3 A number of Acinetobcter
baumannii resistance mechanisms are known
including acquirement of β-lactamases causing
degradation of drugs, up-regulation of multidrug
efflux pumps, modification of aminoglycosides,
permeability defects in cell wall channels
(porins), and alteration of target sites.4 Increasing
multidrug resistance pattern by Acinetobacter
spp.; has narrowed the choice of treatment
by antibiotics. The proper microbiological and
biochemical identification; optimal selection of
antibiotics for susceptibility testing according to
CLSI guidelines along with vigilant employment
of antibiotics; can help in abating the morbidity
and mortality caused by Acinetobacter infections.
www.theprofesional.com
1949
ACINETOBACTER SPECIES
This objective of this study was to determine the
prevalence; and antibiotic sensitivity pattern of
Acinetobacter spp.; among clinical isolates of
tertiary care hospital.
MATERIAL AND METHODS
Sample Collection and Processing
This descriptive study was conducted in Pathology
Department of PGMI, Lahore; during the period
from January 2015 to December 2015. Various
clinical specimens e.g., blood, CSF, pus/wound
swabs, HVS, CVP tip, tracheal secretion, fluid
and urine; were received from patients admitted
in different clinical wards of Lahore General
Hospital (LGH). The specimens were processed
according to standard operating procedures in
microbiology laboratory of Pathology department,
PGMI, Lahore.
2
(15ug), Cefotaxime (30ug), Ceftriaxone (30ug) –
Ceftazidime (30ug), Cefepime (30ug), Aztreonam,
Ciprofloxacin (5ug), Gentamicin (10ug), Amikacin
(30ug), Doxycycline, and Tetracycline (30ug) were
applied; and the plates were incubated at 35˚C
for 24 hours. Acinetobacter baumannii (ATCC)
19606 was used as the quality control strain.
Statistical Analysis
Data will be entered and analyzed using SPSS
Version 20.0 (Statistical Package for Social
Sciences). Qualitative variable i.e., specimen
isolation according to gender, type of specimen
from different clinical wards and antimicrobial
susceptibility were presented as frequencies and
percentages. P values <0.05 are considered
statistically significant.
Culture and Identification
All the samples were primarily inoculated on
blood agar and MacConkey agar; while Cystine
Lactose Electrolyte Deficient (CLED) medium was
used for inoculation of urine samples. The plates
were incubated aerobically at 37oC for 24 hours.
The culture plates were examined for bacterial
growth and colony morphology was noted using
hand lens. Organisms were identified by standard
microbiological and biochemical methods;
including Gram staining, hanging drop, catalase
and oxidase test. On gram staining, Acinetobacter
strains were identified as gram negative bacilli or
coccobacilli, non-motile, oxidase and catalase
positive. Each strain was inoculated on triple
sugar iron (TSI) to see the sugar fermentation
reactions
RESULTS
During the study period from January 2015 to
December 2015; a total of 8465 different clinical
samples were received from Lahore General
Hospital. Out of all the samples processed, 3208
(37.89%) were growth positive after culture. The
overall frequency of Acinetobacter spp. isolates
was 234 (7.29%) in 12 months, as shown in
Table-I. This Table also reveals the distribution of
Acinetobacter spp. isolates from different clinical
specimens (n=234). According to different
specimens, the frequency of Acinetobacter
spp. isolates was highest being isolated from
CSF (23.07%), followed by CVP tip (18,68%),
Fluids (8.49%), Tracheal secretion (7.72%),
Blood (6.39%), Urine (6.34%), Pus/Wound
Swab (5.93%), and HVS (5.52%). Statistically
the difference was significant (p< 0.05) among
percentage of Acinetobacter spp. isolates from
different clinical specimens.
Susceptibility Testing
Antibiotic susceptibility of the Acinetobacter
isolates was determined by employing modified
Kirby-Bauer disc diffusion method according
to CLSI guidelines (2015). For each strain of
Acinetobacter, a bacterial suspension adjusted to
0.5 McFarland turbidity standards was prepared
and inoculated on Mueller Hinton agar (MHA).
Antibiotic discs of Salbactam, Imipenem (10ug),
Piperacillin-Tazobactam (100/10ug), Tigecycline
Positive
Acinetobacter spp.
growth
No.
%age
Pus/ Wound Swab
961
57
5.93
Blood
594
38
6.39
Urine
599
38
6.34
CSF
130
30
23.07
HVS
507
28
5.52
CVP Tip
91
17
18.68
Tracheal Secretion
220
17
7.72
Fluid
106
9
8.49
Total
3208
234
7.29
Table-I. Distribution of Acinetobacter spp. isolated
from different clinical specimen (n=234)
Professional Med J 2018;25(12):1949-1953.
Specimen
www.theprofesional.com
1950
ACINETOBACTER SPECIES
Figure-1 of our study shows; Breakup of
Acinetobacter spp. isolates, from patients
according to gender (n=234). Out of 234 isolates
of Acinetobacter spp., 144 (61.54%) were
recovered from male patients and 90 (38.46%)
from female patients. It shows that frequency was
more in males as compared to females. However,
the difference was statistically non-significant (p
0.05).
3
to amikacin and gentamicin respectively; 164
(70.08%) to ciprofloxacin, 160 (68.37%) and
156 (66.66%) to aztreonam and tetracyclin
respectively. However, 147 (62.82%), 140
(59.82%) and 129 (55.125) isolates were sensitive
to doxycycline, tigecycline, and peracillintazobactam, respectively.
No.
Antibiotics
1
2
Figure-1. Breakup of Acinetobacter spp. isolates
from patients according to gender (n=234)
Table-II shows the frequency of Acinetobacter
spp. isolates from various clinical wards (n=234).
According to this, maximum samples were
recovered from surgical wards 85 (36.32%),
followed by medicine 47 (20.08%), orthopedics
33 (14.10%), gynecology 28 (11.96%), neurology
21 (8.97%) and from pediatrics department 20
(8.54%). Statistically, the difference was nonsignificant (p > 0.05).
Ward
Frequency
Percentage (%)
Surgery
85
36.32
Medicine
47
20.08
Ortho
33
14.10
Gynae
28
11.96
Neuro
21
8.97
Paeds
20
8.54
Table-II. Frequency of Acinetobacter spp. isolated
from various clinical departments (n=234)
Sensitivity pattern of Acinetobacter spp. isolates
to various antibiotics (n=234) is described in
Table-III of our study. It shows that 216 isolates
were (92.30%) resistant to salbactam, followed
by 210 (89.74%) to ceftriaxone, 190 (81.19%)
to cefotaxime, 172 (73.50%) and 162 (69.23%)
Professional Med J 2018;25(12):1949-1953.
Sensitive
(%)
18 (7.69)
90 (38.46)
Resistant
(%)
216 (92.30)
144 (61.53)
Salbactam (SAM)
Imipenem (IPM)
Piperacillin3
129 (55.12) 105 (44.87)
Tazobactam (TZP)
4
Tigecycline (TGC)
140 (59.82)
94 (40.17)
5
Cefotaxime (CTX)
44 (18.80)
190 (81.19)
Ceftriaxone –
6
24 (10.25)
210 (89.74)
Ceftazidime(CRO/CAZ)
7
Cefepime (FEP)
80 (34.18)
154 (65.81)
8
Aztreonam (ATM)
74 (31.62)
160 (68.37)
9
Ciprofloxacin (CIP)
70 (29.91)
164 (70.08)
10
Gentamicin (CN)
72 (30.76)
162 (69.23)
11
Amikacin (AK)
62 (26.49)
172 (73.50)
12
Doxycycline (DO)
147 (62.82)
87 (37.17)
13
Tetracyclin (TCN)
78 (33.33)
156 (66.66)
Table-III. Sensitivity pattern of Acinetobacter spp. to
different antibiotics (n=234)
DISCUSSION
The emergence of pan-resistance in bacterial
pathogens has become a great threat to human
health.5 Among these, the multi-drug resistant
Acinetobacter strains are important cause of
nosocomial infections that are difficult to control
and treat globally including in Pakistan.6
In the present study the prevalence of Acinetobacter
spp. was found to be higher which is inconsistent
with other studies conducted in Pakistan.5,7 The
higher isolation rates of Acinetobacter spp. was
from the CSF in our study. A study from Turkey has
documented Acinetobacter spp. as the leading
cause of Gram-negative postneurosurgical
meningitis.8 In a review done by Kim et al9,
in 2009, describe that Acinetobacter is an
increasingly important pathogen associated with
postneurosurgical meningitis. A study conducted
in Taiwan, Acinetobacter has been ranked the
fifth most common genus to be associated with
nosocomial meningitis.10
www.theprofesional.com
1951
ACINETOBACTER SPECIES
4
The resistance patterns of A. baumannii towards
various antimicrobial agents were determined
by disc diffusion method. A high percentage of
antibiotic resistance of Acinetobacter spp. were
detected for Sulbactam, Imipenem, PiperacillinTazobactam,
Tigecycline,
Cefotaxime,
Ceftriaxone–Ceftazidime, Cefepime, Aztreonam,
Ciprofloxacin,
Amikacin,
Doxycyclin
and
Tetracyclin which is corroborated with findings
of previous reports in different hospitals of Iran,
Turkey and Italy hospital.11,12
fourth generation cephalosporins was reported
in our study. Previously other researchers
also showed high percentage of resistance
among Acinetobacter Spp. against third and
fourth generation cephalosporins.19 [29, 30].
Fluoroquinolone (Ciprofloxacin) resistant strains
in our study were 70.08 % while sensitive strains
were only 29.91 %. Our results are in concordance
with the study conducted by Shamim et al20
in which 88.75% strains were resistant to
ciprofloxacin.
Our study showed highest percentage of
resistance of Acinobacter Spp. to Salbactum. A
study conducted by Begum et al13 in 2013, A.
baumannii exhibited the highest resistance 100%
against β-lactam inhibitors. However, a large
number of studies have shown a high percentage
of sensitivity and effectiveness of Salbactam
based therapies for the treatment of Acinobacter
strains.14
CONCLUSION
The present study revealed the presence of high
prevalence of multiantibiotic resistance isolates
of Acinetobacter spp. in a tertiary care hospital of
Lahore. The progressively increasing resistance
patterns of Acinetobacter infections pose a warning
as therapeutic stalemate. It is recommended that
implementation of strict infection control policy
in every health care setting which includes:
precision of sterilization & disinfection techniques,
hand hygiene, application of universal safety
precautions, and regular hospital surveillance; as
well as optimizing judicial use of antibiotics; can
help to minimize this challenge.
High frequency of carbapenem resistance (61.53
%) was observed in our study. Our results are
in concordance with Hussein et al15 in 2013 in
which (58.26%) isolates showed resistance to
carbapenem. Similarly, a study done by Anwar
et al16 in children hospital Lahore found that
61% isolates of Acinetobacter were resistant to
carbapenem.
It was observed in this study that 44.87 % isolates
were resistant while 55.12% were sensitive
to it. Henwood et al17 in 2002 also showed
resistant strains of Acinetobacter to Piperacillintazobactam.
Tigecycline always remains a good treatment
options for the management of many cases of
infections caused by multidrug resistant strains
of Acinetobacter.7 However, our study showed
40% resistance to tigecycline. Similarly, the
emergence of Acinobacter strains with resistance
against tigecycline is being reported in various
studies.18 Regarding Monobactams, our study
revealed that A. baumannii showed resistance in
68.37% isolates.
High resistance of A. baumannii to third and
Professional Med J 2018;25(12):1949-1953.
ACKNOWLEDGEMENTS
This research was supported by Postgraduate
Medical Institute, Lahore and Lahore General
Hospital, Lahore.
Copyright© 15 Aug, 2018.
REFERENCES
1.
Nithya BR, Gladstone BP, Rodríguez-Baño J, Sifakis F,
Voss A, Carmeli Y, Burkert FR, Gkolia P, Tacconelli E.
Epidemiology and control measures of outbreaks
due to Antibiotic-Resistant or Ganisms in Europe
(EMBARGO): A systematic review protocol. BMJ
open. 2017 Jan 1; 7(1):e013634.
2.
Bodro M, Gudiol C, Garcia-Vidal C, Tubau F, Contra
A, Boix L, Domingo-Domenech E, Calvo M, Carratalà
J. Epidemiology, antibiotic therapy and outcomes
of bacteremia caused by drug-resistant ESKAPE
pathogens in cancer patients. Supportive Care in
Cancer. 2014 Mar 1; 22(3):603-10.
3.
Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P,
Luna B, Spellberg B. Clinical and pathophysiological
overview of Acinetobacter infections: A century of
challenges. Clinical microbiology reviews. 2017 Jan 1;
www.theprofesional.com
1952
ACINETOBACTER SPECIES
5
30(1):409-47.
4.
5.
Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha
CJ, Jeong BC, Lee SH. Biology of Acinetobacter
baumannii: pathogenesis, antibiotic resistance
mechanisms, and prospective treatment options.
Frontiers in cellular and infection microbiology. 2017
Mar 13; 7:55.
Hasan B, Perveen K, Olsen B, Zahra R. Emergence
of carbapenem-resistant Acinetobacter baumannii
in hospitals in Pakistan. Journal of medical
microbiology. 2014 Jan 1; 63(1):50-5.
6.
Sohail M, Rashid A, Aslam B, Waseem M, Shahid M,
Akram M, Khurshid M, Rasool MH. Antimicrobial
susceptibility of Acinetobacter clinical isolates
and emerging antibiogram trends for nosocomial
infection management. Revista da Sociedade Brasileira
de Medicina Tropical. 2016 Jun; 49(3):300-304.
7.
Indhar F, Durrani MA, Bux A, Sohail M. Carbapenemases
among Acinetobacter species isolated from NICU
of a tertiary care hospital in Karachi. JPMA. 2017;
67(1547).
8.
Sacar S, Turgut H, Toprak S, Cirak B, Coskun E, Yilmaz
O, Tekin K. A retrospective study of central nervous
system shunt infections diagnosed in a university
hospital during a 4-year period. BMC infectious
diseases. 2006 Dec; 6(1):43.
9.
Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation
R, Paterson DL. Management of meningitis due to
antibiotic-resistant Acinetobacter species. The
Lancet infectious diseases. 2009 Apr 1; 9(4):245-255.
10. Lu CH, Chang WN, Chang HW. Adult bacterial
meningitis in southern Taiwan: epidemiologic trend
and prognostic factors. Journal of the neurological
sciences. 2000 Dec 15; 182(1):36-44.
11. Aktas O, Ozbek A. Prevalence and in-vitro antimicrobial
susceptibility patterns of Acinetobacter strains
isolated from patients in intensive care units. Journal
of international medical research. 2003 Aug; 31(4):272280.
12. Hakemi VM, Hallajzadeh M, Fallah F, Hashemi A,
Goudarzi H. Characterization of the extended-
spectrum beta-lactamase producers among nonfermenting Gram-negative bacteria isolated from
burnt patients. Archive of Hygiene Sciences, 2013. Jan
2 (1): 1-6.
13. Begum S, Hasan F, Hussain S, Shah AA. Prevalence
of multi drug resistant Acinetobacter baumannii
in the clinical samples from Tertiary Care Hospital
in Islamabad, Pakistan. Pakistan journal of medical
sciences. 2013 Sep; 29(5):1253-1258.
14. Rafailidis PI, Ioannidou EN, Falagas and M.E.
Ampicillin/sulbactam: current status in severe
bacterial infections. Drugs. 2007. Apr: 67: 1829–1849.
15. Hussein HN, Al-Mathkhury JF, Sabbah AM. ImipenemResistant Acinetobacter baumannii isolated from
patients and hospitals environment in Baghdad. Iraqi
Journal of Science. 2013; 54(4):803-12.
16. Anwar M, Ejaz H, Zafar A, Hamid H. Phenotypic
detection of metallo-beta- lactamases in carbapenem
resistant Acinetobacter baumannii isolated from
pediatric patients in Pakistan. Journal of pathogens.
2016 Mar; 2016: 1-6.
17. Henwood CJ, Gatward T, Warner M, James D, Stockdale
MW, Spence RP, Towner KJ, Livermore DM, Woodford
N. Antibiotic resistance among clinical isolates
of Acinetobacter in the UK, and in vitro evaluation
of tigecycline (GAR-936). Journal of Antimicrobial
Chemotherapy. 2002 Mar 1; 49(3):479-487.
18. Gales AC, Jones RN, Sader HS. Global assessment
of the antimicrobial activity of polymyxin B against
54 731 clinical isolates of Gram‐negative bacilli:
Report from the SENTRY antimicrobial surveillance
programme (2001–2004). Clinical microbiology and
infection. 2006 Apr 1; 12(4):315-321.
19. Hakyemez IN, Kucukbayrak A, Tas T, Yikilgan AB,
Akkaya A, Yasayacak A, Akdeniz H. Nosocomial
Acinetobacter baumannii infections and changing
antibiotic resistance. Pakistan journal of medical
sciences. 2013 Sep; 29(5):1245.
20. Shamim S, Abbas M, Qazi MH. Prevalence of Multidrug
Resistant Acinetobacter baumannii in Hospitalized
Patients in Lahore, Pakistan. Pakistan J Mol Med.
2015; 2(1):23-28.
AUTHORSHIP AND CONTRIBUTION DECLARATION
Sr. #
Author-s Full Name
1
Aneela Khawaja
2
Faiqa Arshad
3
Sadaf Aleem
Professional Med J 2018;25(12):1949-1953.
Contribution to the paper
Author=s Signature
Entire research work, Literature review,
Methodology, analysis and write up.
Sample collection and processing,
help in write up.
Sample collection and processing.
www.theprofesional.com
1953